Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy Against Castration-Resistant Prostate Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-10-1033
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Androgen Receptor Inhibitor–induced “BRCAness” and PARP Inhibition Are Synthetically Lethal for Castration-Resistant Prostate Cancer

Science Signaling
BiochemistryCell BiologyMolecular Biology
2017English

STAT3 and STAT5A Are Potential Therapeutic Targets in Castration-Resistant Prostate Cancer

Oncotarget
Oncology
2017English

Ailanthone: A New Potential Drug for Castration-Resistant Prostate Cancer

Chinese Journal of Cancer
2017English

Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer

Cancer Journal
Cancer ResearchOncology
2016English

Salvage Therapy for Castration-Refractory Prostate Cancer Resistant to Docetaxel

Japanese Journal of Urology
Urology
2013English

Inhibition of Hedgehog and Androgen Receptor Signaling Pathways Produced Synergistic Suppression of Castration-Resistant Prostate Cancer Progression

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2013English

Mp52-01 Combination of Indomethacin and Enzalutamide to Treat Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2018English

Aggressive Variants of Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Androgen-Regulated miR-32 Targets BTG2 and Is Overexpressed in Castration-Resistant Prostate Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy